| Myocardial Infarction
Brilinta vs Lipitor
Side-by-side clinical, coverage, and cost comparison for myocardial infarction.Deep comparison between: Brilinta vs Lipitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLipitor has a higher rate of injection site reactions vs Brilinta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lipitor but not Brilinta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brilinta
Lipitor
At A Glance
Oral
Twice daily
P2Y12 platelet inhibitor
Oral
Daily
HMG-CoA reductase inhibitor (statin)
Indications
- Acute Coronary Syndrome
- Myocardial Infarction
- Coronary Artery Disease
- Acute Ischemic Stroke
- Transient Ischemic Attack
- Stent thrombosis
- Myocardial Infarction
- Cerebrovascular accident
- Stable angina
- Diabetes Mellitus, Non-Insulin-Dependent
- Congestive heart failure
- Hyperlipidemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
Dosing
Acute Coronary Syndrome, Myocardial Infarction, Stent thrombosis 180 mg oral loading dose, then 90 mg twice daily for the first year; after one year, 60 mg twice daily; use with aspirin 75-100 mg daily.
Coronary Artery Disease 60 mg twice daily; use with aspirin 75-100 mg daily.
Acute Ischemic Stroke, Transient Ischemic Attack 180 mg loading dose, then 90 mg twice daily for up to 30 days; use with aspirin 300-325 mg loading dose and 75-100 mg daily maintenance.
Myocardial Infarction, Cerebrovascular accident, Stable angina, Diabetes Mellitus Non-Insulin-Dependent, Congestive heart failure, Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia 10 or 20 mg once daily starting; range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily; oral.
Familial hypercholesterolemia - heterozygous Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10 mg once daily starting, range 10-20 mg once daily; oral.
Homozygous Familial Hypercholesterolemia Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10-20 mg once daily starting, range 10-80 mg once daily; oral.
Contraindications
- History of intracranial hemorrhage
- Active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage)
- Hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipient in Lipitor
Adverse Reactions
Most common (>=4%) Dyspnea, dizziness, nausea, bleeding
Serious Major bleeding, fatal/life-threatening bleeding, intracranial hemorrhage, bradycardia, ventricular pauses
Postmarketing Thrombotic Thrombocytopenic Purpura, hypersensitivity reactions including angioedema, central sleep apnea, Cheyne-Stokes respiration, rash
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy and rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, myasthenia gravis exacerbation, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Pharmacology
P2Y12 platelet inhibitor; ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation, with ticagrelor and its active metabolite being approximately equipotent.
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol; it lowers plasma LDL cholesterol and lipoprotein levels by inhibiting hepatic cholesterol synthesis and upregulating LDL receptor expression on hepatic cell surfaces.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brilinta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
Lipitor
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (1/12)
UnitedHealthcare
Brilinta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (3/8)
Lipitor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Brilinta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Lipitor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brilinta.
No savings programs available for Lipitor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrilintaView full Brilinta profile
LipitorView full Lipitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.